Friday, November 18, 2011 3:44:06 PM
Nov14-18 2011: DTRA’s 2011 CBD S&T Conference (LasVegas)
http://cbdstconf2011.sainc.com
“The Defense Threat Reduction Agency (DTRA), executing the Joint Science and Technology Office (JSTO) function within the Chemical & Biological Defense Program (CBDP), invites you to join us at the 2011 Chemical & Biological Defense Science and Technology (CBD S&T) Conference.”
Wednesday Poster Sessions (11-16-2011), track: Therapeutics
http://cbdstconf2011.sainc.com/conference_agenda/WednesdayPosterSession.aspx
. . .I. W15-026 “Phosphatidylserine Targeting Antibodies as Potential Therapeutic Agents for Argentine Hemorrhagic Fever”
Ashley Grant, Univ. of Texas Medical Branch
==> II. W15-048 “Phosphatidylserine as a Therapeutic Target for the Treatment of Francisella Tularensis & Yersinia Pestis Infections”
Cyril Empig*, Peregrine Pharmaceuticals, Inc.
NOTE: *Dr. Cyril Empig was co-author with Dr. Thorpe etal on this 8-2011 presentation by Dr. Thorpe at the Aug 2011 “Intl. Meeting on Cell Biology of Pathogens” in SaoPaulo, Brazil – see http://tinyurl.com/3pjghjz .
- - - - - - -
Dr. Empig’s Poster #W15-048 PDF Posted to PeregrineInc.com 11-18-11:
“Phosphatidylserine as a Therapeutic Target for the Treatment of Francisella Tularensis & Yersinia Pestis Infections”
http://www.peregrineinc.com/images/stories/pdfs/cbdst_bacteria_bavituximab.pdf
Auhor List:
Claire Lonsdale 1, Graeme C. Clark 1, Caroline Rowland 1, Roman Lukaszewski 1, Steven W. King 2, Cyril J. Empig 2, Philip E. Thorpe 3, Rachel E. Dean 1
1 Biomedical Sciences, DSTL Porton Down, Salisbury, Wiltshire, UK
2 Peregrine Pharmaceuticals Inc., 14272 Franklin Ave, Tustin, CA
3 Dept of Pharmacology, Univ. of Texas SW MC, Dallas, TX
- - - - - -
ACKNOWLEDGMENTS:
This research was funded by the Ministry of Defense in the UK. Published with permission of the Defense Science & Technology Laboratory (DSTL) on behalf of the Controller of HMSO. We would like to thank Connie Chang and her team at Peregrine Pharmaceuticals, Inc. (PPHM) for providing the PS-targeting antibody, mch1N11 and isotype control. [Note: AT004 is Fully-Human BAVI=PGN635=1N11]
INTERESTING:
?http://www.dark-places.org.uk/site/dstl-porton-down
”DSTL (Defense Science & Technology Laboratory) Porton Down is one of the most sensitive & secret experimental sites in the UK. The site is based around a technology park conducting scientific & military research, including forensic DNA and a technology transfer initiative - Ploughshare Innovations. Historically, it is also the site which has been linked to many infamous incidents relating to biochemical warfare experiments, also conducted off-site and including spraying public places - Salisbury & Weymouth, for example. Site is adjacent to MOD Boscombe Down and the entire area is wrapped by a large area of land which is declared as a Danger Zone. . . In 1995, the Establishment became part of the Defense Evaluation & Research Agency (DERA), an executive agency of MOD evolved in 1994 from proposals of the "Front Line First" Defense Cost Studies. In 2001, DERA split into 2 organisations: QinetiQ, a private company, and DSTL (Defense Science & Technology Laboratory), which remains an agency of MOD. Porton Down is now known as DSTL Porton Down.”
http://www.peregrineinc.com/images/stories/pdfs/cbdst_bacteria_bavituximab.pdf
*end*
Recent CDMO News
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:33:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:32:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:31:12 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM